Technical Analysis for PRLD - Prelude Therapeutics Incorporated
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Flat | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Earnings Movers | Other | -2.97% | |
| Outside Day | Range Expansion | -2.97% | |
| Wide Bands | Range Expansion | -2.97% | |
| Gapped Up | Strength | -2.97% | |
| Down 3 Days in a Row | Weakness | -2.97% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -6.27% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 18 hours ago |
| Rose Above 10 DMA | about 18 hours ago |
| Fell Below Previous Day's Low | about 20 hours ago |
| Down 2 % | about 20 hours ago |
| 60 Minute Opening Range Breakdown | about 21 hours ago |
Get a Trading Assistant
- Earnings date: 05/06/2024
Prelude Therapeutics Incorporated Description
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Lymphoma Blastoma Glioblastoma Protein Kinase Inhibitor Tyrosine Kinase Receptors Small Molecule Therapies Glioblastoma Multiforme Phosphoinositide 3 Kinase Inhibitor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.875 |
| 52 Week Low | 1.66 |
| Average Volume | 44,595 |
| 200-Day Moving Average | 3.59 |
| 50-Day Moving Average | 4.40 |
| 20-Day Moving Average | 4.14 |
| 10-Day Moving Average | 3.84 |
| Average True Range | 0.35 |
| RSI (14) | 37.89 |
| ADX | 23.96 |
| +DI | 16.00 |
| -DI | 25.96 |
| Chandelier Exit (Long, 3 ATRs) | 4.78 |
| Chandelier Exit (Short, 3 ATRs) | 4.47 |
| Upper Bollinger Bands | 5.41 |
| Lower Bollinger Band | 2.86 |
| Percent B (%b) | 0.29 |
| BandWidth | 61.81 |
| MACD Line | -0.22 |
| MACD Signal Line | -0.18 |
| MACD Histogram | -0.0377 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.11 | ||||
| Resistance 3 (R3) | 4.16 | 4.05 | 4.02 | ||
| Resistance 2 (R2) | 4.05 | 3.92 | 4.02 | 3.99 | |
| Resistance 1 (R1) | 3.82 | 3.84 | 3.76 | 3.76 | 3.96 |
| Pivot Point | 3.70 | 3.70 | 3.68 | 3.68 | 3.70 |
| Support 1 (S1) | 3.48 | 3.57 | 3.42 | 3.42 | 3.22 |
| Support 2 (S2) | 3.36 | 3.49 | 3.33 | 3.19 | |
| Support 3 (S3) | 3.13 | 3.36 | 3.16 | ||
| Support 4 (S4) | 3.07 |
